Legacy Pharmaceutical Packaging, LLC Issues Voluntary Nationwide Recall of Losartan Potassium Tablets, USP, 25mg, 50mg, And 100mg Due to The Detection of Trace Amounts Of N-Nitroso N-Methyl 4-Amino Butyric Acid (NMBA) Impurity Found in The Active Pharmaceutical Ingredient (API)
Earth City, MO, Legacy Pharmaceutical Packaging, LLC is recalling 40 repackaged lots of Losartan Tablets USP 25mg, 50mg, and 100mg to the consumer level. This recall was prompted due to Camber Pharmaceuticals, Inc. issuing a Voluntary Nationwide Recall of Losartan Tablets, USP, due to the detection (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - July 23, 2019 Category: Drugs & Pharmacology Authors: FDA Source Type: news
Two MORE blood pressure drugs recalled over carcinogens
Macleods Pharmaceuticals voluntarily recalled 32 lots of two types of its losartan blood pressure medication that contain unsafe levels of the carcinogen NMBA, the US FDA announced on Wednesday (Source: the Mail online | Health)
Source: the Mail online | Health - June 28, 2019 Category: Consumer Health News Source Type: news
ARB Concerns Continue as Macleods Pulls Contaminated Losartan ARB Concerns Continue as Macleods Pulls Contaminated Losartan
The recall comes amid renewed concerns after a recent expanded recall and the discovery of a fourth potential carcinogen in another commonly used hypertension and heart failure medication.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - June 27, 2019 Category: Cardiology Tags: Cardiology News Source Type: news
Macleods Pharmaceutical Limited Issues Voluntary Nationwide Consumer Level Recall of Losartan Potassium 50mg and Losartan Potassium/Hydrochlorothiazide combination Tablets 50mg/12.5mg, 100mg/12.5mg and 100mg/25mg due to detection of NMBA (N-Nitroso-N Methyl-4-aminobutyric acid) Impurity.
Macleods Pharmaceuticals Limited has initiated a voluntary recall in the United States, to the patient level, of 32 lots of Losartan Potassium USP Tablets (2 lots of 50mg strength) and Losartan Potassium/Hydrochlorothiazide combination Tablets (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - June 27, 2019 Category: Drugs & Pharmacology Authors: FDA Source Type: news
Pharmacy Tests Turn Up Another Cancer-Causing Compound In Heart Drugs
(CNN) — Tests by an online pharmacy turned up another cancer-causing compound in heart medications, and these drugs haven’t been recalled.
Drugs containing valsaratan, losartan and irbesartan made by a variety of companies in a variety of countries have been taken off pharmacy shelves since July, when tests turned up chemicals in them that are considered carcinogens. The recalls of these angiotensin II receptor blockers or ARBs continue to expand. The US Food and Drug Administration keeps a regularly updated list of the drugs that have been recalled.
In this case, it’s not a recall. Instead, Valisure, an ...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - June 19, 2019 Category: Consumer Health News Authors: Health – CBS Boston Tags: Health News CNN Valsartan Source Type: news
Teva Pharmaceuticals Expands Losartan Recall
Teva Pharmaceuticals Expands Patient-Level Losartan Recall (Source: eMedicineHealth.com)
Source: eMedicineHealth.com - June 13, 2019 Category: General Medicine Source Type: news
Teva Pharmaceuticals Expands Patient-Level Losartan Recall Teva Pharmaceuticals Expands Patient-Level Losartan Recall
The new recall of six lots brings the total to 41 lots of bulk losartan potassium sold to Golden State Medical Supply of California.News Alerts (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - June 12, 2019 Category: Cardiology Tags: Cardiology News Alert Source Type: news
Teva Pharmaceuticals USA, Inc. Expands Voluntary Nationwide Recall of Losartan Potassium to 50 mg and 100 mg Tablets USP, Sold Exclusively to Golden State Medical Supply, Inc.
This expanded recall includes six (6) lots of bulk losartan potassium USP Tablets (two lots of 50 mg strength and four lots of 100 mg strength) due to the detection of an impurity – N-Nitroso-N-methyl-4-aminobutyric acid (NMBA) (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - June 12, 2019 Category: Drugs & Pharmacology Authors: FDA Source Type: news
Novel Neoadjuvant Approach May Boost Surgical Success in Pancreatic Cancer Novel Neoadjuvant Approach May Boost Surgical Success in Pancreatic Cancer
In the majority of studied patients with locally advanced pancreatic cancer, total neoadjuvant treatment with fluorouracil, leucovorin, oxaliplatin and irinotecan (FOLFIRINOX) along with losartan and chemoradiation allowed complete tumor removal, according to a single-arm phase 2 trial.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 10, 2019 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
UPDATED: Torrent Pharmaceuticals Limited Issues Voluntary Nationwide Recall of Losartan Potassium Tablets, USP and Losartan Potassium and Hydrochlorothiazide Tablets, USP
Torrent Pharmaceuticals Limited is expanding its voluntary recall from 10 lots of Losartan potassium tablets USP to include 6 lots of Losartan potassium and hydrochlorothiazide tablets, USP, to the consumer level due to the detection of trace amounts of an unexpected impurity. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - June 5, 2019 Category: Drugs & Pharmacology Authors: FDA Source Type: news
Vivimed Life Sciences Pvt Ltd Issues Voluntary Nationwide Recall of Losartan Potassium 25 mg, 50 mg and 100 mg Tablets, USP Due to the Detection of Trace Amounts of N-Nitroso-N-methyl-4-aminobutyric acid (NMBA) Impurity
Vivimed Life Sciences Pvt Ltd (Vivimed) is recalling 19 lots of Losartan Potassium Tablets USP 25 mg, 50 mg, and 100 mg to consumer level. Due to the detection of an impurity – N-Nitroso-N-methyl-4-aminobutyric acid (NMBA). (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - June 4, 2019 Category: Drugs & Pharmacology Authors: FDA Source Type: news
Trial: Gains Seen on Inoperable Pancreatic Cancer
In the clinical trial, 49 patients with locally advanced pancreatic cancer received intensive chemotherapy and radiation therapy, as well as the blood pressure drug losartan. (Source: WebMD Health)
Source: WebMD Health - May 30, 2019 Category: Consumer Health News Source Type: news
Novel protocol significantly improves outcomes in locally advanced pancreatic cancer
(Massachusetts General Hospital) A Massachusetts General Hospital Cancer Center clinical trial of a protocol combining intensive chemotherapy and radiation therapy with the blood pressure drug losartan has produced unprecedented results in patients with locally advanced pancreatic cancer, allowing complete removal of the tumor in 61% of participants and significantly improving survival rates. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 30, 2019 Category: Cancer & Oncology Source Type: news
Torrent Pharmaceuticals Limited Issues Voluntary Nationwide Recall of Losartan Potassium Tablets, USP
Torrent Pharmaceuticals Limited is voluntarily recalling 2 lots of Losartan potassium tablets, USP to the consumer level due to the detection of trace amounts of an unexpected impurity found in an active pharmaceutical ingredient (API) manufactured by Hetero Labs Limited. The impurity detected in th (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - May 21, 2019 Category: Drugs & Pharmacology Authors: FDA Source Type: news
Macleods Pharmaceuticals Limited Issues Voluntary Nationwide Consumer Level Recall of One Lot (BLM 715A) of Losartan Potassium/Hydrochlorothiazide Combination Tablets 100mg/25mg Due to detection of NDEA (N-Nitrosodiethylamine) Impurity
Macleods Pharmaceuticals Limited is voluntarily recalling one lot of Losartan Potassium/Hydrochlorothiazide combination tablets 100mg/25mg to the consumer level due to the detection of trace amounts of an unexpected impurity (NDEA) found in finished product manufactured with active pharmaceutical in (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - May 21, 2019 Category: Drugs & Pharmacology Authors: FDA Source Type: news
